These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

549 related items for PubMed ID: 38379863

  • 21. A glycosylated hemoglobin A1c above 6% (42 mmol/mol) is associated with a high risk of developing Cystic Fibrosis-Related Diabetes and a lower probability of weight gain in both adults and children with Cystic Fibrosis.
    Potter KJ, Racine F, Bonhoure A, Boudreau V, Bélanger N, Coriati A, Shohoudi A, Lavoie A, Senior PA, Mailhot G, Rabasa-Lhoret R.
    Diabetes Metab; 2023 Jul; 49(4):101455. PubMed ID: 37271306
    [Abstract] [Full Text] [Related]

  • 22. Peak OGTT glucose is associated with lower lung function in young children with cystic fibrosis.
    Prentice BJ, Chelliah A, Ooi CY, Hameed S, Verge CF, Plush L, Widger J.
    J Cyst Fibros; 2020 Mar; 19(2):305-309. PubMed ID: 31126898
    [Abstract] [Full Text] [Related]

  • 23. Study of Glycemic Variability in Well-controlled Type 2 Diabetic Patients Using Continuous Glucose Monitoring System.
    Swami V, Yadav SK, Saxena P, Sharma A, Dash CK, Gupta A.
    J Assoc Physicians India; 2024 Jan; 72(1):18-21. PubMed ID: 38736069
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. The course of glucose intolerance in children with cystic fibrosis: a retrospective study - preliminary report.
    Piechowiak K, Trippenbach-Dulska H, Walicka-Serzysko K.
    Dev Period Med; 2015 Jan; 19(1):80-91. PubMed ID: 26003073
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Peak glucose during an oral glucose tolerance test is associated with future diabetes risk in adults with cystic fibrosis.
    Bonhoure A, Potter KJ, Colomba J, Boudreau V, Bergeron C, Desjardins K, Carricart M, Tremblay F, Lavoie A, Rabasa-Lhoret R.
    Diabetologia; 2021 Jun; 64(6):1332-1341. PubMed ID: 33693987
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Continuous glucose monitoring abnormalities in cystic fibrosis youth correlate with pulmonary function decline.
    Chan CL, Vigers T, Pyle L, Zeitler PS, Sagel SD, Nadeau KJ.
    J Cyst Fibros; 2018 Nov; 17(6):783-790. PubMed ID: 29580828
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Continuous glucose monitoring versus self-monitoring of blood glucose in the management of cystic fibrosis related diabetes: A systematic review and meta-analysis.
    Kumar S, Soldatos G, Ranasinha S, Teede H, Pallin M.
    J Cyst Fibros; 2023 Jan; 22(1):39-49. PubMed ID: 35906171
    [Abstract] [Full Text] [Related]

  • 36. Impact of triple transmembrane regulator therapy on glucose metabolism in cystic fibrosis related diabetes during clinical practice.
    Aguilera García I, García Moreno RM, López Plaza B, Barquiel Alcalá B, Vázquez Pérez P, Barreda Bonis AC, Zamarrón de Lucas E, Palma Milla S, Prados Sánchez MC, González Pérez de Villar N.
    Diabetes Res Clin Pract; 2024 Oct; 216():111839. PubMed ID: 39187175
    [Abstract] [Full Text] [Related]

  • 37. Abnormal glucose tolerance in children with cystic fibrosis: the predictive role of continuous glucose monitoring system.
    Schiaffini R, Brufani C, Russo B, Fintini D, Migliaccio A, Pecorelli L, Bizzarri C, Lucidi V, Cappa M.
    Eur J Endocrinol; 2010 Apr; 162(4):705-10. PubMed ID: 20071479
    [Abstract] [Full Text] [Related]

  • 38. Clinical updates in cystic fibrosis-related diabetes.
    Brennan AL, Beynon J.
    Semin Respir Crit Care Med; 2015 Apr; 36(2):236-50. PubMed ID: 25826591
    [Abstract] [Full Text] [Related]

  • 39. Effect of CFTR modulator therapy on cystic fibrosis-related diabetes.
    Gaines H, Jones KR, Lim J, Medhi NF, Chen S, Scofield RH.
    J Diabetes Complications; 2021 Jun; 35(6):107845. PubMed ID: 33558149
    [Abstract] [Full Text] [Related]

  • 40. Glycated Hemoglobin as a First-line Screening Test for Cystic Fibrosis‒Related Diabetes and Impaired Glucose Tolerance in Children With Cystic Fibrosis: A Validation Study.
    Racine F, Shohoudi A, Boudreau V, Nguyen CQT, Denis MH, Desjardins K, Reynaud Q, Rabasa-Lhoret R, Mailhot G.
    Can J Diabetes; 2021 Dec; 45(8):768-774. PubMed ID: 33926819
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 28.